The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

Following the demerger of ITC Hotels from ITC Ltd, Nuvama expects an outflow of approximately $180 million due to the ...

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...

JM Financial forecasts Jio’s ARPU to rise 4.5% QoQ to ₹204. Bharti Airtel is expected to see 4.8% QoQ growth in India ...

Niftys earnings per share (EPS) expected by a modest 2 per cent year-on-year (YoY) in the third quarter of FY25, according to ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

Media companies expected to report muted Q3FY25 results with some segments showing growth, but overall performance remains ...

TARIL is undertaking an ambitious capacity expansion program, which will not only make the company India’s largest ...